GPE – Page 19 – Talk Bio

Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.

Boehringer Ingelheim and Zealand Unveil Promising Fibrosis Data from Mid-Stage MASH Trial

11 months ago talkbio0Tagged boehringer ingelheim, Clinical Trials, Fibrosis, liver scarring, MASH, mid-stage, Phase II, Zealand

Boehringer Ingelheim, Zealand, fibrosis, MASH trial, mid-stage, Phase II data, liver scarring, treatment

Bristol Myers Squibb to Cut Over 860 Jobs in New Jersey as Part of $1.5 Billion Savings Campaign

11 months ago talkbio0Tagged Drug Industry, Financial cost, Financial savings, Myers, New Jersey, savings campaign, squibb

Bristol Myers Squibb, job cuts, New Jersey, $1.5 billion savings campaign, cost savings, pharmaceutical industry

Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment

11 months ago talkbio0Tagged Diabetes, Eli, Eli Lilly, Fibrosis, GLP-1/GIP Dual Agonist, Liver diseases, MASH, Obesity, tirzepatide

Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

11 months ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)